CG_Financial

AMGN Long Term Long

Long
NASDAQ:AMGN   Amgen Inc.
Top pharma pick right now other than BMY. P/E 13.11 with forecasted 6-7% earnings growth and an EPS yield of 7.62%.

Historic Norm P/E 18.89
^ 10 Y = 14.50
^ 5 Y = 14.25
3.49% Div payer.

Valuation estimate based on 2023 forecasted EPS (19.11) and P/E of 14.25 = $272.32
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.